These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-000243-23 An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma 2007-05-09 due-trials
Reported results 2004-003771-37 A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis ... 2007-04-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-006163-31 A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz... 2012-06-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001433-17 A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref... 2013-05-23 bad-data
Ongoing 2006-002472-17 An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with... not-yet-due
Completed, but no date Terminated 2006-003184-31 A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pu... bad-data
Completed, but no date 2006-003252-38 An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis bad-data
Listed as ongoing, but also has a completion date 2006-003353-24 Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Myco... 2009-11-16 bad-data
Listed as ongoing, but also has a completion date 2006-004516-51 A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement 2008-12-02 bad-data
Listed as ongoing, but also has a completion date 2006-004945-40 A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer... 2008-10-09 bad-data
Not reported Terminated 2007-002945-18 A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthriti... 2007-12-17 due-trials
Reported results 2007-002950-42 A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a... 2015-07-15 due-trials
Ongoing, reported early 2007-002951-18 A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-004190-26 An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant 2014-08-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004223-38 A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients 2011-10-26 bad-data
Exempt 2007-005690-59 A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patien... not-yet-due
Listed as ongoing, but also has a completion date 2008-000582-39 An Open label single arm trial investifating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma ... 2011-08-31 bad-data
Listed as ongoing, but also has a completion date 2008-000781-23 An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with ... 2010-10-18 bad-data
Exempt 2009-013317-10 An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN 2011-10-31 not-yet-due
Exempt 2011-005692-16 An Open-label, International, Multicenter, Dose Escalating 2013-03-01 not-yet-due
Exempt, with results 2015-001120-29 Dose-escalating and cohort expansion safety trial of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors k... 2017-12-13 not-yet-due
Listed as ongoing, but also has a completion date 2016-004743-37 A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factor 2020-01-31 bad-data
Exempt 2017-001394-16 First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors not-yet-due
Ongoing 2017-003413-25 A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer not-yet-due